Skip to main content

Advertisement

Table 1 Patient characteristics

From: Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer

Patients Age/Sex Tumor site* Prior therapy** Peptide
   Primary Metastases   (mg)
1 38/F IBD Lung, bone Ope, GEM, CBDCA, TS-1, DTX 1
2 69/M GB Liver, LN Ope, GEM, TS-1 1
3 60/F GB Liver, LN Ope, GEM, TS-1 1
4 66/F IBD Liver, lung, LN, bone Ope, GEM, TS-1 2
5 75/M IBD Lung Ope, GEM, TS-1 2
6 61/F IBD Liver, LN, peritoneum GEM, TS-1, CDDP 2
7 46/M EBD Liver, LN Ope, GEM, TS-1 3
8 76/M EBD Lung Ope, GEM, TS-1 3
9 62/F EBD Lung Ope, GEM, TS-1 3
  1. *IBD: intrahepatic bile duct; GB: gallbladder; EBD: extrahepatic bile duct; LN: lymph node.
  2. **Ope: operation; GEM: gemcitabine; CBDCA: carboplatin; TS-1: tegafur-gimeracil-oteracil potassium; DTX: docetaxcel; CDDP: cisplatin.